If reopening the economy after the prolonged shutdown was the end of the beginning, then the successful...
OPINION
Experts Point of View
Intellectual Property Providing access to medicines at affordable prices while maintaining incentives for the...
Immatics Biotechnologies has landed a potential US$1.1bn deal with GlaxoSmithKline (GSK) to find novel cancer...
Every year, it’s the same: in January, investors are scratching their heads, searching to find investment...
While open innovation may be seen as a way of cutting costs by shutting down in-house R&D in favour of...
Spanish 3P Biopharmaceuticals has shown tremendous growth, at least 10 per cent above market growth rate in...
Share
